Guangdong Hybribio Biotech Co.,Ltd.

300639

CNE100002N51

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 16/07/2024 BST			5-day change	1st Jan Change
4.58 ^CNY	+0.66%		+2.23%	-50.96%

07-16	Guangdong Hybribio Biotech Obtains License for Clinical Laboratory Instruments	MT
07-02	Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on June 28, 2024.	CI

Guangzhou Hybribio Medical Testing Development Co., Ltd. announced that it has received CNY 340 million in funding from a group of investors

January 16, 2018

On January 17, 2018, Guangzhou Hybribio Medical Testing Development Co., Ltd closed the transaction. The company completed the change of business registration of its capital increase.

Latest news about Guangdong Hybribio Biotech Co.,Ltd.

Guangdong Hybribio Biotech Obtains License for Clinical Laboratory Instruments	07-16	MT
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on June 28, 2024.	07-02	CI
Guangdong Hybribio Biotech Co.,Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	06-27	CI
Guangdong Hybribio Biotech Co.,Ltd. authorizes a Buyback Plan.	06-26	CI
Hybribio Biotech Gets Patent for Spinal Muscular Atrophy Gene Kit	05-21	MT
Hybribio Biotech Unit Gets Nod to Market Deafness Gene Detection Kit in China	05-16	MT
Guangdong Hybribio Biotech Co.,Ltd. Approves Cash Dividend for the Year 2023	05-15	CI
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024.	05-07	CI
Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback announced on February 6, 2024, has closed with 4,445,000 shares, representing 1.51% for CNY 30.1 million.	05-06	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Dividend for the Year 2023	04-23	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-23	CI
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024.	04-01	CI
Guangdong Hybribio Biotech, Subsidiary Get Patent from Brazil for Isolation Method	03-22	MT
Hybribio Biotech's Unit Secures Registration Certificate for Nucleic Acid Analysis System	02-23	MT
Guangdong Hybribio Biotech Co.,Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	02-05	CI
Guangdong Hybribio Biotech Co.,Ltd. authorizes a Buyback Plan.	02-04	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/10/23	CI
Two Guangdong Hybribio Biotech Units Get Licenses from Drug Regulator	04/09/23	MT
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23	CI
Guangdong Hybribio Biotech Registers Gene Testing Kit	18/08/23	MT
Hybribio Showcases Cutting-Edge Cervical Cancer HPV Diagnostic Solutions At ADLM 2023	31/07/23	CI
Hybribio Biotech Appoints Chief Medical Officer	27/06/23	MT
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on October 26, 2022.	24/05/23	CI
Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback announced on October 26, 2022 has closed with 5,937,000 shares, representing 0.91% for CNY 100 million.	22/05/23	CI

Chart Guangdong Hybribio Biotech Co.,Ltd.

Duration

Period

Chart Guangdong Hybribio Biotech Co.,Ltd.

More charts

Guangdong Hybribio Biotech Co Ltd is a company mainly engaged in production and sales of vitro diagnostic reagents. The Company operates two segments. The In Vitro Diagnostic Reagents and Supporting Equipment segment operates the research, development and production of nucleic acid detection reagents and supporting equipment, such as cervical cancer detection series products, deafness susceptibility gene detection series products and reproductive health management series products. The products are used in hospital clinical testing, large-scale population screening and other areas. The Medical Testing Service segment is involved in providing medical testing services for medical institutions, and the testing programs cover genetic metabolic diseases, infectious diseases, molecular pathological testing and tumor examinations.

Sector

Medical Equipment, Supplies & Distribution

Calendar

28/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.58

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GUANGDONG HYBRIBIO BIOTECH CO.,LTD.	-50.96%	405M
BIOMÉRIEUX	-6.61%	12.14B
LANTHEUS HOLDINGS, INC.	+96.15%	8.43B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-18.38%	6.91B
DIASORIN S.P.A.	+9.13%	5.93B
AUTOBIO DIAGNOSTICS CO., LTD.	-21.66%	3.57B
ANDON HEALTH CO., LTD.	+5.36%	2.53B
MYRIAD GENETICS, INC.	+41.54%	2.45B
VITROLIFE AB	+17.72%	2.94B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-18.43%	1.59B

Diagnostic & Testing Substances

Guangdong Hybribio Biotech Co.,Ltd.

Equities

300639

CNE100002N51

Medical Equipment, Supplies & Distribution

Guangzhou Hybribio Medical Testing Development Co., Ltd. announced that it has received CNY 340 million in funding from a group of investors

Latest news about Guangdong Hybribio Biotech Co.,Ltd.

Chart Guangdong Hybribio Biotech Co.,Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Diagnostic & Testing Substances